Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?

Suppr

超能文献

作者信息

Ogilvie Lesley A, Jones Brian V

出版信息

Gut. 2012 Nov;61(11):1642-3. doi: 10.1136/gutjnl-2012-302137. Epub 2012 Apr 5.

DOI:10.1136/gutjnl-2012-302137

PMID:22490526

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3463861/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc89/3463861/dc51bd19cf3e/gutjnl-2012-302137fig1.jpg

相似文献

Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?

Gut. 2012 Nov;61(11):1642-3. doi: 10.1136/gutjnl-2012-302137. Epub 2012 Apr 5.

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17.

FXR activation inhibits inflammation and preserves the intestinal barrier in IBD.

Gut. 2011 Apr;60(4):432-3. doi: 10.1136/gut.2010.233304. Epub 2011 Jan 26.

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.

Gastroenterology. 2018 Dec;155(6):1741-1752.e5. doi: 10.1053/j.gastro.2018.08.022. Epub 2018 Aug 23.

Nuclear receptors, bile-acid detoxification, and cholestasis.

Lancet. 2006 Feb 11;367(9509):454-6. doi: 10.1016/S0140-6736(06)68156-7.

Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease.

World J Gastroenterol. 2023 Jul 21;29(27):4252-4270. doi: 10.3748/wjg.v29.i27.4252.

Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.

World J Gastroenterol. 2018 Jun 7;24(21):2320-2326. doi: 10.3748/wjg.v24.i21.2320.

Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice.

J Crohns Colitis. 2021 Jul 5;15(7):1197-1210. doi: 10.1093/ecco-jcc/jjab003.

Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1422-1437. doi: 10.1016/j.bbalip.2019.07.006. Epub 2019 Jul 17.

Differential effects of two bile salts on ion transport characteristics of teleost intestine.

Comp Biochem Physiol A Comp Physiol. 1987;86(2):367-72. doi: 10.1016/0300-9629(87)90344-6.

引用本文的文献

Emerging concepts and shifting paradigms for understanding the microbial basis of inflammatory bowel diseases.

J Clin Invest. 2025 Sep 2;135(17). doi: 10.1172/JCI193969.

Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.

J Bacteriol. 2025 Sep 18;207(9):e0016725. doi: 10.1128/jb.00167-25. Epub 2025 Aug 18.

Nanomedicine Strategies in the Management of Inflammatory Bowel Disease and Colorectal Cancer.

Int J Mol Sci. 2025 Jul 4;26(13):6465. doi: 10.3390/ijms26136465.

Investigation of Bile Salt Hydrolase Activity in Human Gut Bacteria Reveals Production of Conjugated Secondary Bile Acids.

bioRxiv. 2025 Jan 16:2025.01.16.633392. doi: 10.1101/2025.01.16.633392.

Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis.

Pharmaceuticals (Basel). 2024 Mar 7;17(3):347. doi: 10.3390/ph17030347.

The role of human milk fats in shaping neonatal development and the early life gut microbiota.

Microbiome Res Rep. 2023 Mar 31;2(2):8. doi: 10.20517/mrr.2023.09. eCollection 2023.

From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.

Biomedicines. 2023 Sep 28;11(10):2658. doi: 10.3390/biomedicines11102658.

LA39 promotes hepatic primary bile acid biosynthesis and intestinal secondary bile acid biotransformation.

J Zhejiang Univ Sci B. 2023 Aug 15;24(8):734-748. doi: 10.1631/jzus.B2200439.

The role of complex interactions between the intestinal flora and host in regulating intestinal homeostasis and inflammatory bowel disease.

Front Microbiol. 2023 Jun 14;14:1188455. doi: 10.3389/fmicb.2023.1188455. eCollection 2023.

BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway.

Front Pharmacol. 2023 May 24;14:1205323. doi: 10.3389/fphar.2023.1205323. eCollection 2023.

本文引用的文献

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17.

A human gut microbial gene catalogue established by metagenomic sequencing.

Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821.

Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13580-5. doi: 10.1073/pnas.0804437105. Epub 2008 Aug 29.

Targeting bile-acid signalling for metabolic diseases.

Nat Rev Drug Discov. 2008 Aug;7(8):678-93. doi: 10.1038/nrd2619.

Nutrition and colonic health: the critical role of the microbiota.

Curr Opin Gastroenterol. 2008 Jan;24(1):51-8. doi: 10.1097/MOG.0b013e3282f323f3.

Bile salt biotransformations by human intestinal bacteria.

J Lipid Res. 2006 Feb;47(2):241-59. doi: 10.1194/jlr.R500013-JLR200. Epub 2005 Nov 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验